inclusion criteria: - male and female over 18 years old (18 years inclusive). - has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen as diagnosed within 72 hours prior to randomization. - expected to survive for at least 96 hours after study entry. - if patient is a female of childbearing potential, patient must use an effective means of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined hormonal contraceptives or intrauterine devices or sexual abstinence). - subject or legally authorized representative understands and agrees to comply with planned study procedures. - subject or legally authorized representative provides informed consent prior to initiation of any study procedures.

inclusion criteria: - male and female over 18 years old (18 years inclusive). - has laboratory-confirmed sars-cov-2 infection as determined by pcr, or other commercial or public health assay in any specimen as diagnosed within 72 hours prior to randomization. - expected to survive for at least 96 hours after study entry. - if patient is a female of childbearing potential, patient must use an effective means of birth control (oral, intravaginal or transdermal oestrogen-progestogen combined hormonal contraceptives or intrauterine devices or sexual abstinence). - subject or legally authorized representative understands and agrees to comply with planned study procedures. - subject or legally authorized representative provides informed consent prior to initiation of any study procedures.